Arrowstreet Capital
BIIB icon

Arrowstreet Capital’s Biogen BIIB Stock Holding History

Arrowstreet Capital’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-45,349
Closed -$7.98M – 1849
2025
Q4 		$7.98M Sell
45,349
-335,442
-88% -$54.8M ﹤0.01% 999
2025
Q3 		$53.3M Sell
380,791
-243,580
-39% -$32.9M 0.03% 445
2025
Q2 		$78.4M Buy
624,371
+409,591
+191% +$51M 0.06% 315
2025
Q1 		$29.4M Buy
+214,780
New +$30.7M 0.02% 483
2023
Q4 		– Sell
-196,954
Closed -$50.6M – 1409
2023
Q3 		$50.6M Sell
196,954
-98,889
-33% -$26.4M 0.06% 249
2023
Q2 		$84.3M Buy
295,843
+5,103
+2% +$1.52M 0.1% 175
2023
Q1 		$80.8M Sell
290,740
-156,059
-35% -$43.2M 0.1% 189
2022
Q4 		$124M Sell
446,799
-183,697
-29% -$51.9M 0.17% 136
2022
Q3 		$168M Buy
630,496
+40,394
+7% +$8.58M 0.25% 104
2022
Q2 		$120M Sell
590,102
-397,975
-40% -$81.4M 0.17% 135
2022
Q1 		$208M Buy
988,077
+22,215
+2% +$4.83M 0.26% 103
2021
Q4 		$232M Buy
965,862
+691,743
+252% +$178M 0.28% 89
2021
Q3 		$77.6M Buy
274,119
+87,302
+47% +$28.6M 0.1% 231
2021
Q2 		$64.7M Buy
+186,817
New +$56.6M 0.08% 273
2021
Q1 		– Sell
-316,606
Closed -$77.5M – 2249
2020
Q4 		$77.5M Buy
316,606
+18,301
+6% +$4.72M 0.11% 168
2020
Q3 		$84.6M Sell
298,305
-412,294
-58% -$115M 0.13% 140
2020
Q2 		$190M Sell
710,599
-735,860
-51% -$221M 0.35% 47
2020
Q1 		$458M Sell
1,446,459
-973,732
-40% -$296M 1.29% 7
2019
Q4 		$718M Sell
2,420,191
-242,164
-9% -$67.2M 1.67% 7
2019
Q3 		$620M Buy
2,662,355
+167,598
+7% +$39M 1.45% 7
2019
Q2 		$583M Buy
2,494,757
+778,167
+45% +$180M 1.3% 7
2019
Q1 		$406M Buy
1,716,590
+192,501
+13% +$60.6M 0.96% 20
2018
Q4 		$459M Buy
1,524,089
+94,227
+7% +$30.1M 1.2% 13
2018
Q3 		$505M Sell
1,429,862
-376,925
-21% -$130M 1.14% 17
2018
Q2 		$524M Buy
1,806,787
+662,933
+58% +$186M 1.28% 11
2018
Q1 		$313M Buy
1,143,854
+1,094,854
+2,234% +$340M 0.72% 32
2017
Q4 		$15.6M Buy
+49,000
New +$15.7M 0.04% 348
2017
Q3 		– Sell
-159,300
Closed -$43.2M – 1099
2017
Q2 		$43.2M Buy
159,300
+154,200
+3,024% +$40.8M 0.13% 166
2017
Q1 		$1.39M Buy
+5,100
New +$1.44M 0.01% 895
2016
Q1 		– Sell
-289,253
Closed -$88.6M – 1341
2015
Q4 		$88.6M Sell
289,253
-317,757
-52% -$91.3M 0.41% 52
2015
Q3 		$177M Buy
607,010
+304,100
+100% +$100M 0.84% 20
2015
Q2 		$122M Buy
302,910
+300,810
+14,324% +$121M 0.69% 31
2015
Q1 		$887K Buy
+2,100
New +$828K 0.01% 737
2014
Q4 		– Sell
-332,814
Closed -$110M – 1231
2014
Q3 		$110M Buy
332,814
+80,913
+32% +$26.7M 0.59% 38
2014
Q2 		$79.4M Sell
251,901
-418,208
-62% -$126M 0.41% 55
2014
Q1 		$205M Sell
670,109
-21,445
-3% -$6.81M 1.24% 13
2013
Q4 		$193M Buy
691,554
+7,381
+1% +$1.91M 1.05% 13
2013
Q3 		$165M Buy
684,173
+66,404
+11% +$14.9M 1.05% 17
2013
Q2 		$133M Buy
+617,769
New +$132M 0.99% 19

Other funds holding BIIB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Arrowstreet Capital's BIIB Position: Q1 2026 in Review

Arrowstreet Capital sold out of Biogen (BIIB) in Q1 2026, closing a stake of 45,349 shares — an estimated $7.98M sold.

Arrowstreet Capital first reported a position in BIIB in Q2 2013 and held it in 39 quarters. The position peaked at $718M in Q4 2019. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.

  • Arrowstreet Capital reported no remaining Biogen position as of Q1 2026 after selling out during the quarter.
  • Arrowstreet Capital sold 45,349 Biogen shares in Q1 2026, an estimated $7.98M.
  • Arrowstreet Capital first reported a position in Biogen in Q2 2013 and held it in 39 quarters.
  • Arrowstreet Capital's Biogen position peaked at $718M in Q4 2019.
  • 1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.

Based on Arrowstreet Capital's 13F filing for Q1 2026, filed 14 May 2026.